Diabetic Foot Ulcers
Conditions
Keywords
non healing wound
Brief summary
The aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, case-matched cohort trial in which diabetic foot ulcers (DFU) will be treated using AutoloGel and case-matched against a concurrent cohort of patients receiving undefined Usual and Customary Care (UCC) as provided in up to 30 U.S. Wound Registry Research Network (USWRRN) centers.
Detailed description
AutoloGel is a platelet-rich plasma gel used in the treatment of non-healing chronic wounds. Prospective observational studies of the effectiveness of AutoloGel have demonstrated promising results in regard to the healing of DFUs, including severe Wagner grade 3 and 4 ulcers. The aim of this trial is to demonstrate the effectiveness of complete wound healing in a prospective, open-label, case-matched cohort trial in which diabetic foot ulcers will be treated using AutoloGel to determine the time to heal at 12 weeks. Comparison will be made with a case-matched concurrent cohort of patients receiving undefined Usual and Customary Care (UCC).
Interventions
DEVICEAutoloGel
AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
Sponsors
Cytomedix
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Medicare/Medicaid eligible 2. ≥18 years of age 3. Type I or II diabetes requiring medical treatment as determined by the physician 4. The largest non-healing wound, if multiple wounds are present, or the single wound to be treated (Index Ulcer) is a Wagner 1-5 DFU (see Appendix 9 for Wagner Classification) that is located on the dorsal, plantar, medial, or lateral aspect of the foot or heel (including all toe surfaces) 5. For subjects with potentially multiple eligible DFUs, the largest ulcer will be selected There must be at least 4 cm between the Index Ulcer and other ulcers; if all ulcers are closer than 4 cm, the subject should not be enrolled (screen failure) 6. Debrided ulcer size between 0.5 cm2 and 50 cm2 7. Demonstrated adequate offloading regimen 8. Duration ≥ 1 month at first visit 9. Subject must be willing to comply with the Protocol, which will be assessed by enrolling clinician.
Exclusion criteria
1. Subjects known to be sensitive to AutoloGel components (calcium chloride, thrombin, ascorbic acid) and/or materials of bovine origin 2. Presence of another wound that is concurrently treated and might interfere with treatment of the index wound by AutoloGel (malignancy in nearby wound) 3. Ulcer not of DFU pathophysiology (e.g., venous, vasculitic, radiation, rheumatoid, collagen vascular disease, pressure, or arterial etiology) 4. Any malignancy other than non-melanoma skin cancer 5. Subjects who are cognitively impaired and do not have a healthcare proxy 6. Serum albumin of less than 2.5 g/dL 7. Plasma Platelet count of less than 100 x 109/L 8. Hemoglobin of less than 10.5 g/dL 9. Subject has inadequate venous access for repeated blood draw required for AutoloGel Administration.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Time to heal | 12 weeks | The primary objective of the trial is to determine the time to heal diabetic foot ulcers treated with Autologel and Standard of Care at 12 weeks DFUs. Comparison will be made with a concurrent cohort of case matched subjects |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Ulcer recurrence | 1 year | Frequency of ulcer recurrence defined as any new ulcer appearing after the index ulcer healed |
| Incidence of amputations | 1 year | Frequency of lower extremity amputations; major/minor amputations will be tabulated but not tested. |
| Proportion of completely healed ulcers | 12 weeks | Proportion of patients with completely healed diabetic foot ulcers |
| W-QOL (Quality of life with Chronic Wounds) score | 12 weeks | Change in mean W-QOL (Quality of life with Chronic Wounds) score between baseline and 12 weeks |
| Number of patients with adverse events as a measure of tolerability | 12 weeks | Frequency and severity of adverse events |
Countries
United States
Outcome results
None listed